Joseph R Leventhal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7949420/publications.pdf

Version: 2024-02-01

109264 128225 3,963 109 35 60 citations g-index h-index papers 115 115 115 3213 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation. Science Translational Medicine, 2012, 4, 124ra28.	5.8	376
2	THE IMMUNOPATHOLOGY OF CARDIAC XENOGRAFT REJECTION IN THE GUINEA PIG-TO-RAT MODEL. Transplantation, 1993, 56, 1-8.	0.5	188
3	Alemtuzumab Induction and Prednisone-Free Maintenance Immunotherapy in Kidney Transplantation: Comparison with Basiliximab Induction-Long-Term Results. American Journal of Transplantation, 2005, 5, 2539-2548.	2.6	178
4	A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants. Scientific Reports, 2018, 8, 7428.	1.6	178
5	Resolution of Recurrent Focal Segmental Glomerulosclerosis after Retransplantation. New England Journal of Medicine, 2012, 366, 1648-1649.	13.9	157
6	Tolerance Induction in HLA Disparate Living Donor Kidney Transplantation by Donor Stem Cell Infusion. Transplantation, 2013, 95, 169-176.	0.5	143
7	A PROSPECTIVE STUDY OF RAPID CORTICOSTEROID ELIMINATION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION. Transplantation, 2002, 73, 169-177.	0.5	134
8	Laparoscopic donor nephrectomy 1997 to 2003: Lessons learned with 500 cases at a single institution. Surgery, 2004, 136, 881-890.	1.0	129
9	Immune Reconstitution/Immunocompetence in Recipients of Kidney Plus Hematopoietic Stem/Facilitating Cell Transplants. Transplantation, 2015, 99, 288-298.	0.5	122
10	LAPAROSCOPIC LIVE DONOR NEPHRECTOMY???IS IT SAFE?. Transplantation, 2000, 70, 602-606.	0.5	117
11	Are Concerns Over Right Laparoscopic Donor Nephrectomy Unwarranted?. Annals of Surgery, 2001, 233, 645-651.	2.1	110
12	Proposed classification of complications after live donor nephrectomy. Urology, 2006, 67, 927-931.	0.5	86
13	The Complexity of Human Leukocyte Antigen (HLA)-DQ Antibodies and Its Effect on Virtual Crossmatching. Transplantation, 2010, 90, 1117-1124.	0.5	75
14	Epitope Analysis of HLA-DQ Antigens. Transplantation, 2014, 98, 157-166.	0.5	68
15	Reduction of CMV Disease with Steroid-Free Immunosuppresssion in Simultaneous Pancreas-Kidney Transplant Recipients. American Journal of Transplantation, 2005, 5, 1423-1429.	2.6	67
16	MYCOPHENOLATE MOFETIL AND TACROLIMUS AS PRIMARY MAINTENANCE IMMUNOSUPPRESSION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION. Transplantation, 1999, 67, 586-593.	0.5	63
17	Genomic Biomarkers Correlate with HLA-Identical Renal Transplant Tolerance. Journal of the American Society of Nephrology: JASN, 2013, 24, 1376-1385.	3.0	60
18	Targeting Acute Allograft Rejection by Immunotherapy With Ex Vivo-Expanded Natural CD4+CD25+ Regulatory T Cells. Transplantation, 2006, 82, 1749-1755.	0.5	58

#	Article	lF	Citations
19	LOW BIOAVAILABILITY OF CYCLOSPORINE MICROEMULSION AND TACROLIMUS IN A SMALL BOWEL TRANSPLANT RECIPIENT. Transplantation, 1999, 67, 333-335.	0.5	55
20	EVIDENCE THAT 15-DEOXYSPERGUALIN INHIBITS NATURAL ANTIBODY PRODUCTION BUT FAILS TO PREVENT HYPERACUTE REJECTION IN A DISCORDANT XENOGRAFT MODEL. Transplantation, 1992, 54, 26-31.	0.5	53
21	Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology, 2013, 57, 239-248.	3.6	52
22	Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. Transplantation, 2015, 99, 1774-1784.	0.5	51
23	RISK FACTORS AND IMPACT OF CYTOMEGALOVIRUS DISEASE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION. Transplantation, 2001, 72, 1940-1945.	0.5	48
24	Tolerance induction in HLA disparate living donor kidney transplantation by facilitating cell-enriched donor stem cell Infusion: The importance of durable chimerism. Human Immunology, 2018, 79, 272-276.	1.2	47
25	A decade of minimally invasive donation: experience with more than 1200 laparoscopic donor nephrectomies at a single institution. Clinical Transplantation, 2010, 24, 169-174.	0.8	46
26	Tackling Chronic Kidney Transplant Rejection: Challenges and Promises. Frontiers in Immunology, 2021, 12, 661643.	2.2	45
27	Sequential Kidney/Islet Transplantation Using Prednisone-Free Immunosuppression. American Journal of Transplantation, 2002, 2, 674-677.	2.6	44
28	Long-Term Kidney Allograft Function and Survival in Prednisone-Free Regimens. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 504-512.	2.2	44
29	The DQ Barrier. Transplantation, 2013, 95, 635-640.	0.5	43
30	Surgical techniques in right laparoscopic donor nephrectomy 11No competing interests declared Journal of the American College of Surgeons, 2002, 195, 131-137.	0.2	41
31	Long-Term Renal Transplant Function in Recipient of Simultaneous Kidney and Pancreas Transplant Maintained With Two Prednisone-Free Maintenance Immunosuppressive Combinations: Tacrolimus/Mycophenolate Mofetil Versus Tacrolimus/Sirolimus. Transplantation, 2007, 83, 1324-1329.	0.5	41
32	Defining the Alloreactive T Cell Repertoire Using High-Throughput Sequencing of Mixed Lymphocyte Reaction Culture. PLoS ONE, 2014, 9, e111943.	1,1	41
33	Cellular rejection in discordant xenografts when hyperacute rejection is prevented: analysis using adoptive and passive transfer. Transplant Immunology, 1994, 2, 87-93.	0.6	39
34	IgY antiporcine endothelial cell antibodies effectively block human antiporcine xenoantibody binding. Xenotransplantation, 1999, 6, 98-109.	1.6	38
35	Generation and Characterization of Alloantigen-Specific Regulatory T Cells For Clinical Transplant Tolerance. Scientific Reports, 2018, 8, 1136.	1.6	38
36	Leukopenia Complicates Cytomegalovirus Prevention After Renal Transplantation With Alemtuzumab Induction. Transplantation, 2007, 83, 874-882.	0.5	37

#	Article	IF	Citations
37	Laparoscopic Living Donor Nephrectomy: A Single-Center Sequential Experience Comparing Hand-Assisted Versus Standard Technique. Urology, 2007, 70, 1060-1063.	0.5	37
38	The Human "Treg MLR― Immune Monitoring for FOXP3+ T Regulatory Cell Generation. Transplantation, 2009, 88, 1303-1311.	0.5	36
39	Allospecific Regulatory Effects of Sirolimus and Tacrolimus in the Human Mixed Lymphocyte Reaction. Transplantation, 2011, 91, 199-206.	0.5	34
40	Antigen Specificity Enhances Disease Control by Tregs in Vitiligo. Frontiers in Immunology, 2020, 11, 581433.	2.2	34
41	Effect of Prednisone versus No Prednisone as Part of Maintenance Immunosuppression on Long-Term Renal Transplant Function. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1029-1038.	2.2	33
42	Antibody Removal by Column Immunoabsorption Prevents Tissue Injury in an Ex Vivo Model of Pig-to-Human Xenograft Hyperacute Rejection. Journal of Surgical Research, 1995, 59, 43-50.	0.8	32
43	Pretransplant Evaluation of Renal Transplant Candidates. Seminars in Nephrology, 2002, 22, 515-525.	0.6	30
44	HLA-DQ Barrier. Transplantation, 2013, 96, 1065-1072.	0.5	29
45	Summary of the Third International Workshop on Clinical Tolerance. American Journal of Transplantation, 2019, 19, 324-330.	2.6	29
46	Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus. Kidney International, 2015, 87, 828-838.	2.6	28
47	The Fourth International Workshop on Clinical Transplant Tolerance. American Journal of Transplantation, 2021, 21, 21-31.	2.6	28
48	Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells. Journal of the American Society of Nephrology: JASN, 2017, 28, 1960-1972.	3.0	26
49	Tailoring Antibody Testing and How to Use it in the Calculated Panel Reactive Antibody Era: The Northwestern University Experience. Transplantation, 2008, 86, 1052-1059.	0.5	24
50	SYNTHETIC PEPTIDES WHICH INHIBIT THE INTERACTION BETWEEN $\rm C1_{q}$ AND IMMUNOGLOBULIN AND PROLONG XENOGRAFT SURVIVAL1. Transplantation, 2000, 70, 828-836.	0.5	23
51	HSCT-Based Approaches for Tolerance Induction in Renal Transplant. Transplantation, 2017, 101, 2682-2690.	0.5	21
52	Piscine Islet Xenotransplantation. ILAR Journal, 2004, 45, 314-323.	1.8	20
53	The emergence of xenotransplantation. Transplant Immunology, 1995, 3, 21-31.	0.6	19
54	Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Human Immunology, 2012, 73, 141-149.	1.2	19

#	Article	IF	CITATIONS
55	Outstanding questions in transplantation: Tolerance. American Journal of Transplantation, 2020, 20, 348-354.	2.6	19
56	Clinical trial of islet xenotransplantation in Mexico. Xenotransplantation, 2006, 13, 371-372.	1.6	18
57	Updated follow-up of a tolerance protocol in HLA-identical renal transplant pairs given donor hematopoietic stem cells. Human Immunology, 2018, 79, 277-282.	1.2	18
58	Effect of glucose toxicity on intraportal tilapia islet xenotransplantation in nude mice. Xenotransplantation, 2005, 12, 189-196.	1.6	16
59	Ureteral Complications in the Era of Laparoscopic Living Donor Nephrectomy: Do We Need to Preserve the Gonadal Vein with the Specimen?. Journal of Endourology, 2010, 24, 247-251.	1.1	16
60	Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. Transplantation, 2017, 101, 1056-1066.	0.5	15
61	KIDNEY TRANSPLANTATION WITHOUT PREDNISONE Transplantation, 2000, 69, S133.	0.5	14
62	EVIDENCE THAT RAT XENOREACTIVE ANTIBODIES RECOGNIZE MULTIPLE PROTEIN ANTIGENS ON GUINEA PIG ENDOTHELIAL CELLS AND PLATELETS. Transplantation, 1994, 58, 458-466.	0.5	13
63	Facilitating cells in tolerance induction for kidney transplantation. Current Opinion in Organ Transplantation, 2015, 20, 57-63.	0.8	12
64	Chimerism and tolerance: past, present and future strategies to prolong renal allograft survival. Current Opinion in Nephrology and Hypertension, 2021, 30, 63-74.	1.0	12
65	Facilitating cells: Translation of hematopoietic chimerism to achieve clinical tolerance. Chimerism, 2015, 6, 33-39.	0.7	11
66	Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses. PLoS ONE, 2016, 11, e0156535.	1.1	11
67	Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2018, 29, 423-433.	3.0	11
68	Cellular and functional biomarkers of clinical transplant tolerance. Human Immunology, 2018, 79, 322-333.	1.2	10
69	Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen—Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil. PLoS ONE, 2019, 14, e0216300.	1.1	9
70	Evidence that tilapia islets do not express alpha- $(1,3)$ gal: implications for islet xenotransplantation. Xenotransplantation, 2004, 11, 276-283.	1.6	8
71	Microchimerism in promoting graft acceptance in clinical transplantation. Current Opinion in Organ Transplantation, 2011, 16, 345-352.	0.8	8
72	Is durable macrochimerism key to achieving clinical transplantation tolerance?. Current Opinion in Organ Transplantation, 2011, 16, 343-344.	0.8	8

#	Article	IF	CITATIONS
73	Clinical transplant tolerance: Coming of age. Human Immunology, 2018, 79, 255-257.	1.2	8
74	Radiotherapy for Rejection of Renal Transplant Allografts Refractory to Medical Immunosuppression. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 551-554.	0.6	7
75	Reply to 'Critics slam Russian trial to test pig pancreas for diabetes'. Nature Medicine, 2007, 13, 662-663.	15.2	7
76	Renal allograft function in kidney transplant recipients infected with SARS-CoV 2: An academic single center experience. PLoS ONE, $2021, 16, e0252979$.	1.1	7
77	Transplanting a Kidney with a Renal Artery Aneurysm. Vascular Surgery, 2001, 35, 321-324.	0.3	6
78	Transcriptomic studies in tolerance: Lessons learned and the path forward. Human Immunology, 2018, 79, 395-401.	1.2	6
79	Clinical Implications of Basic Science Discoveries: Induced Pluripotent Stem Cell Therapy in Transplantation—A Potential Role for Immunologic Tolerance. American Journal of Transplantation, 2015, 15, 887-890.	2.6	5
80	Varying levels of X chromosome coalescence in female somatic cells alters the balance of X-linked dosage compensation and is implicated in female-dominant systemic lupus erythematosus. Scientific Reports, 2019, 9, 8011.	1.6	5
81	Bone marrow-derived AXL tyrosine kinase promotes mitogenic crosstalk and cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2021, 40, 435-446.	0.3	4
82	Pre-transplant infusion of donor leukocytes treated with extracorporeal photochemotherapy induces immune hypo-responsiveness and long-term allograft survival in murine models. Scientific Reports, 2022, 12, 7298.	1.6	4
83	Two Rare Forms of Renal Allograft Glomerulopathy During Cytomegalovirus Infection and Treatment. American Journal of Kidney Diseases, 2008, 51, 1047-1051.	2.1	3
84	Arguments against the Requirement of a Biological License Application for Human Pancreatic Islets: The Position Statement of the Islets for US Collaborative Presented during the FDA Advisory Committee Meeting. Journal of Clinical Medicine, 2021, 10, 2878.	1.0	3
85	Requirement of Cognate CD4+ T-Cell Recognition for the Regulation of Allospecific CTL by Human CD4+CD127â^'CD25+FOXP3+ Cells Generated in MLR. PLoS ONE, 2011, 6, e22450.	1.1	3
86	Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review. Blood, 2020, 136, 9-10.	0.6	3
87	Late conversion of tacrolimus to sirolimus in a prednisoneâ€free immunosuppression regimen in renal transplant patients. Clinical Transplantation, 2010, 24, 199-206.	0.8	2
88	Chimerism and Tolerance Without Gvhd In Mismatched Recipients Of Combined Hematopoietic Stem Cell/Kidney Transplants: Donor-Specific Hyporeactivity Is Not a Reliable Biomarker For Tolerance. Blood, 2013, 122, 912-912.	0.6	2
89	Establishment of Durable Chimerism with Minimal GvHD in Highly Mismatched Recipients Receiving an Investigational Facilitated Allo-HSCT. Blood, 2021, 138, 911-911.	0.6	2
90	Beyond Hyperacute Rejection. Transplantation, 1995, 59, 171-176.	0.5	2

#	Article	IF	CITATIONS
91	Long-term Follow-up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients. Transplantation, 2018, 102, S394.	0.5	1
92	Cell therapy can enable minimization of immunosuppression. Nature Reviews Nephrology, 2020, 16, 486-487.	4.1	1
93	Immune Reconstitution in Recipients of Living Donor Kidney/Hematopoietic Stem + Facilitating Cell Transplants. Blood, 2014, 124, 191-191.	0.6	1
94	ALTERED INFECTIVITY OF PORCINE ENDOGENOUS RETROVIRUS BY â€∞PROTECTIVE―AVIAN ANTIBODIES: IMPLICATIONS FOR PIG-TO-HUMAN XENOTRANSPLANTATION Transplantation, 2000, 69, S418.	0.5	0
95	ALLOGENEIC TRANSPLANTATION INDUCES HCMV IMMEDIATE EARLY GENE EXPRESSION AND ACTIVATES NFκB Transplantation, 2000, 69, S385.	0.5	0
96	Xenotransplant News. Xenotransplantation, 2003, 10, 95-95.	1.6	0
97	OR26. Human Immunology, 2014, 75, 21.	1.2	0
98	P011. Human Immunology, 2014, 75, 56.	1.2	0
99	Abdominal pain and vomiting in a pancreas transplant recipient. American Journal of Transplantation, 2018, 18, 2362-2364.	2.6	0
100	Achieving Solid Organ Transplant Tolerance: New Findings, More Questions and the Search Continues. Transplantation, 2020, 104, 1531-1532.	0.5	0
101	HLA MOLECULAR MISMATCH ANALYSIS IN PATIENTS RECEIVING KIDNEY AND THE HEMATOPOIETIC STEM / FACILITATING CELL INDUCTION PROTOCOL. Transplantation, 2020, 104, S50-S50.	0.5	0
102	Durable Chimerism, Absence of Graft-Versus-Host Disease and the Induction of Donor Specific Tolerance in Recipients of HLA Disparate Living Donor Kidney Transplants and Therapeutic Cell Transfer. Blood, 2011, 118, 832-832.	0.6	0
103	Chimerism, Lymphocyte Recovery, and the Absence of Graft-Versus-Host Disease in Recipients of Mismatched Unrelated Combined Kidney and HSC Transplants for Tolerance Induction. Blood, 2011, 118, 1969-1969.	0.6	O
104	Evaluation Of Immunocompentence In Tolerant Chimeric Recipients Of Hematopoietic Stem Cell/Renal Transplants. Blood, 2013, 122, 4483-4483.	0.6	0
105	Update On Phase 2 Clinical Trial To Induce Tolerance In Mismatched Living Donor Renal Transplant Recipients. Blood, 2013, 122, 4622-4622.	0.6	O
106	ALLOGENEIC TRANSPLANTATION OF LATENTLY INFECTED KIDNEYS INDUCES EXPRESSION OF MCMV LYTIC REPLICATION CYCLE GENES IN VIVO. Transplantation, 1999, 67, S604.	0.5	0
107	Use of a Processed Hematopoietic Stem Cell Product (FCRx) in Unmatched Related and Unrelated Donor â€" Recipient Pairs Is Associated with High Levels of Donor Chimerism and Donor-Specific Tolerance to Kidney Allografts. Blood, 2018, 132, 202-202.	0.6	0
108	DIAGNOSIS OF KIDNEY TRANSPLANT REJECTION BY TRACKING DONOR-REACTIVE T-CELL CLONES IN THE POST-TRANSPLANT BIOPSY, BLOOD AND URINE SAMPLES. Transplantation, 2020, 104, S30-S30.	0.5	0

#	Article	IF	CITATIONS
109	Establishment of Durable Chimerism with Minimal GvHD in Highly Mismatched Recipients Receiving an Investigational Facilitated Allo-HSCT. Transplantation and Cellular Therapy, 2022, 28, S74-S75.	0.6	O